The three Rs along the TRAIL: Resistance, re-sensitization and reactive oxygen species (ROS)

References

• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–12690.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, . Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3: 673–682.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157–163.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, . Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–162.
   PubMed Web of Science ®Google Scholar
• Koschny R, Walczak H, Ganten TM. The promise of TRAIL—potential and risks of a novel anticancer therapy. J Mol Med 2007;85:923–935.
   PubMed Web of Science ®Google Scholar
• LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66–75.
   PubMed Web of Science ®Google Scholar
• Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, Demuth T, Berens ME. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003;116(Pt 21):4409–4417.
   PubMed Web of Science ®Google Scholar
• Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111–113.
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815–818.
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, . Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818–821.
   PubMed Web of Science ®Google Scholar
• Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, . A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003–1006.
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363–14367.
   PubMed Web of Science ®Google Scholar
• Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997;16:2794–2804.
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579–5588.
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611–620.
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205–219.
   PubMed Web of Science ®Google Scholar
• Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139–163.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007;14:1237–1243.
   PubMed Web of Science ®Google Scholar
• Waterhouse NJ, Ricci JE, Green DR. And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochimie 2002;84:113–121.
   PubMed Web of Science ®Google Scholar
• Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405–413.
   PubMed Web of Science ®Google Scholar
• Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002;4:551–557.
   PubMed Web of Science ®Google Scholar
• Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 1999;15:793–802.
   Google Scholar
• Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, . Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005;3:335–343.
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, . Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003;10:356–364.
   PubMed Web of Science ®Google Scholar
• Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, . Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001;20:399–403.
   PubMed Web of Science ®Google Scholar
• Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, . Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942–4946.
   PubMed Web of Science ®Google Scholar
• Jin Z, McDonald ER, 3rd, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004;279:35829–35839.
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006;26:7046–7055.
   PubMed Web of Science ®Google Scholar
• Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 2001;276:27322–27328.
   PubMed Web of Science ®Google Scholar
• Shenoy K, Wu Y, Pervaiz S. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res 2009;69:1941–1950.
   PubMed Web of Science ®Google Scholar
• Jung EM, Park JW, Choi KS, Lee HI, Lee KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis 2006;27: 2008–2017.
   PubMed Web of Science ®Google Scholar
• Kim H, Kim EH, Eom YW, Kim WH, Kwon TK, Lee SJ, Choi KS. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 2006;66:1740–1750.
   Google Scholar
• Earel JK, Jr., VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006;66:499–507.
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region. Mol Cancer Ther 2008;7:1091–1100.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, . Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 2005;65:5662–5667.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Um HJ, Min do S, Park JW, Choi KS, Kwon TK. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 2009;46:1639–1649.
   PubMed Web of Science ®Google Scholar
• Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, . Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 2007;67:8274–8284.
   PubMed Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, . Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070–1077.
   PubMed Web of Science ®Google Scholar
• Rossin A, Derouet M, Abdel-Sater F, Hueber AO. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J 2009;419:185–192, 2 p following 192.
   PubMed Web of Science ®Google Scholar
• Cremesti AE, Goni FM, Kolesnick R. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett 2002;531: 47–53.
   PubMed Web of Science ®Google Scholar
• Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 2005;65:11447–11458.
   PubMed Web of Science ®Google Scholar
• Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007;6:2591–2599.
   PubMed Web of Science ®Google Scholar
• Poh TW, Huang S, Hirpara JL, Pervaiz S. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ 2007;14:1813–1825.
   PubMed Web of Science ®Google Scholar
• Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem 2005;280: 11641–11647.
   PubMed Web of Science ®Google Scholar
• Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, . Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004;23:8979–8986.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu H, Teraishi F, Davis JJ, Guo W, Fan Z, Fang B. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 2005;7:594–602.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 2008;7:1156–1163.
   PubMed Web of Science ®Google Scholar
• Dolcet X, Llobet D, Pallares J, Rue M, Comella JX, Matias-Guiu X. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005;85:885–894.
   PubMed Web of Science ®Google Scholar
• Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, . Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 2008;27:3211–3220.
   Google Scholar
• Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, . Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 2008;44:1055–1068.
   PubMed Web of Science ®Google Scholar
• Thorpe JA, Christian PA, Schwarze SR. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 2008;68: 200–209.
   PubMed Web of Science ®Google Scholar
• Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705–711.
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 2003;63:1712–1721.
   PubMed Web of Science ®Google Scholar
• Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res 2002;62: 1583–1587.
   PubMed Web of Science ®Google Scholar
• Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002;16:33–45.
   PubMed Web of Science ®Google Scholar
• LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, . Tumor-cell resistance to death receptor— induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002;8:274–281.
   PubMed Web of Science ®Google Scholar
• Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, . Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004;64:3517–3524.
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228–237.
   PubMed Web of Science ®Google Scholar
• Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, Wu GS. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001;280:788–797.
   PubMed Web of Science ®Google Scholar
• Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008;68:2944–2951.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14 - 1, in human colon cancer cells. Clin Cancer Res 2004;10: 8284–8292.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Gaiser T, Habel A, Siegelin Y. Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. Neurosci Lett 2009;454:223–228.
   PubMed Web of Science ®Google Scholar
• Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther 2002;1:1051–1058.
   PubMed Web of Science ®Google Scholar
• Connolly K, Mitter R, Muir M, Jodrell D, Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol 2009;64:307–316.
   PubMed Web of Science ®Google Scholar
• Gill C, Dowling C, O'Neill AJ, Watson RW. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 2009;8:39.
   PubMed Web of Science ®Google Scholar
• Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001;61:7339–7348.
   PubMed Web of Science ®Google Scholar
• Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, . Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009;69: 2425–2434.
   Google Scholar
• Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009;113: 1710–1722.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, . TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004;61:1965–1974.
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim SU, Choi KS. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005;24:838–849.
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446–456.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Reuss DE, Habel A, Herold-Mende C, von Deimling A. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Mol Cancer Ther 2008;7:3566–3574.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Reuss DE, Habel A, Rami A, von Deimling A. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol 2009;11:122–131.
   PubMed Web of Science ®Google Scholar
• Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007;47:143–183.
   PubMed Web of Science ®Google Scholar
• Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci 2004;24:7779–7788.
   PubMed Web of Science ®Google Scholar
• Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. Sci STKE 2006;2006:re8.
   PubMedGoogle Scholar
• Zhang AY, Yi F, Zhang G, Gulbins E, Li PL. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006;47:74–80.
   PubMed Web of Science ®Google Scholar
• Leto TL, Morand S, Hurt D, Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 2009;11:2607–2619.
   PubMed Web of Science ®Google Scholar
• Bonekamp NA, Volkl A, Fahimi HD, Schrader M. Reactive oxygen species and peroxisomes: struggling for balance. Biofactors 2009;35:346–355.
   PubMed Web of Science ®Google Scholar
• Zangar RC, Davydov DR, Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol 2004;199:316–331.
   PubMed Web of Science ®Google Scholar
• Ursini F, Maiorino M, Brigelius-Flohe R, Aumann KD, Roveri A, Schomburg D, Flohe L. Diversity of glutathione peroxidases. Methods Enzymol 1995;252:38–53.
   PubMed Web of Science ®Google Scholar
• Carlberg I, Mannervik B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J Biol Chem 1975;250:5475–5480.
   PubMed Web of Science ®Google Scholar
• Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000;346(Pt 1):1–8.
   PubMed Web of Science ®Google Scholar
• Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000;267:6102–6109.
   PubMedGoogle Scholar
• Goyal MM, Basak A. Human catalase: looking for complete identity. Protein Cell 2010;1:888–897.
   PubMed Web of Science ®Google Scholar
• Clement MV, Pervaiz S. Reactive oxygen intermediates regulate cellular response to apoptotic stimuli: an hypothesis. Free Radic Res 1999;30:247–252.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992;119:598–620.
   PubMed Web of Science ®Google Scholar
• Clement MV, Pervaiz S. Intracellular superoxide and hydrogen peroxide concentrations: a critical balance that determines survival or death. Redox Rep 2001;6:211–224.
   PubMed Web of Science ®Google Scholar
• Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47–95.
   PubMed Web of Science ®Google Scholar
• Ahmad KA, Clement MV, Pervaiz S. Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induced apoptosis. Ann N Y Acad Sci 2003;1010:365–373.
   PubMed Web of Science ®Google Scholar
• Clement MV, Hirpara JL, Pervaiz S. Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ 2003;10:1273–1285.
   PubMed Web of Science ®Google Scholar
• Clement MV, Stamenkovic I. Superoxide anion is a natural inhibitor of FAS-mediated cell death. EMBO J 1996;15:216–225.
   PubMed Web of Science ®Google Scholar
• Clement MV, Ponton A, Pervaiz S. Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. FEBS Lett 1998;440:13–18.
   PubMed Web of Science ®Google Scholar
• Ahmad KA, Iskandar KB, Hirpara JL, Clement MV, Pervaiz S. Hydrogen peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during drug-induced apoptosis of tumor cells. Cancer Res 2004;64: 7867–7878.
   PubMed Web of Science ®Google Scholar
• Hirpara JL, Clement MV, Pervaiz S. Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J Biol Chem 2001;276:514–521.
   PubMed Web of Science ®Google Scholar
• Rao GN. Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases. Oncogene 1996;13:713–719.
   PubMed Web of Science ®Google Scholar
• Lim S, Clement MV. Phosphorylation of the survival kinase Akt by superoxide is dependent on an ascorbate-reversible oxidation of PTEN. Free Radic Biol Med 2007;42:1178–1192.
   PubMed Web of Science ®Google Scholar
• Pervaiz S, Cao J, Chao OS, Chin YY, Clement MV. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene 2001;20:6263–6268.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Chou CW, Chang YF, Chen CC. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J Immunol 2008;180: 8030–8039.
   PubMed Web of Science ®Google Scholar
• Prasad S, Yadav VR, Ravindran J, Aggarwal BB. ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res;71: 538–549.
   PubMed Web of Science ®Google Scholar
• Park KJ, Lee CH, Kim A, Jeong KJ, Kim CH, Kim YS. Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death. J Biol Chem 2012;287:3313–3325.
   PubMed Web of Science ®Google Scholar